3/6/2009

Regulating the development of follow-on biologics as recommended in President Barack Obama's first budget could benefit patients if the law "appropriately balances the need for competition with the need to protect innovation," writes James Bianco, CEO and director of Cell Therapeutics. The law should help bring follow-on biologics to the market quickly but only after their safety and efficacy have been tested in clinical trials, Bianco writes.

Related Summaries